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Abstract
Background: Helicobacter pylori is an important pathogenic factor in gastric carcinogenesis. Angiogenesis (i.e., the
growth of new blood vessels) is closely associated with the incidence and development of gastric cancer. Our
previous study found that COX-2 stimulates gastric cancer cells to induce expression of the angiogenic growth
factor VEGF through an unknown mechanism. Therefore, the aim of this study was to clarify the role of
angiogenesis in H. pylori-induced gastric cancer development.
Methods: To clarify the relationship between H. pylori infection and angiogenesis, we first investigated H. pylori
colonization, COX-2, VEGF, beta-catenin expression, and microvessel density (MVD) in gastric cancer tissues from
106 patients. In addition, COX-2, phospho-beta-catenin, and beta-catenin expression were measured by western
blotting, and VEGF expression was measured by ELISA in H. pylori-infected SGC7901 and MKN45 human gastric
cancer cells.
Results: H. pylori colonization occurred in 36.8 % of gastric carcinoma samples. Furthermore, COX-2, beta-catenin,
and VEGF expression, and MVD were significantly higher in H. pylori-positive gastric cancer tissues than in H.
pylori-negative gastric cancer tissues (P < 0.01). H. pylori infection was not related to sex or age in gastric cancer
patients, but correlated with the depth of tumor invasion, lymph node metastasis, and tumor–node–metastasis
stage (P < 0.05) and correlated with the COX-2 expression and beta-catenin expression(P < 0.01). Further cell
experiments confirmed that H. pylori infection upregulated VEGF in vitro. Further analysis revealed that H.
pylori-induced VEGF expression was mediated by COX-2 via activation of the Wnt/beta-catenin pathway.
Conclusions: The COX-2/Wnt/beta-catenin/VEGF pathway plays an important role in H. pylori-associated gastric
cancer development. The COX-2/Wnt/beta-catenin pathway is therefore a novel therapeutic target for H.
pylori-associated gastric cancers.
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Background
Helicobacter pylori is a Gram-negative, spiral bacillus that
infects approximately half the world’s population and in-
duces chronic inflammation of the gastric mucosa, con-
tributing to the development of peptic ulcer and gastric
malignancies [1, 2]. H. pylori has been classified as a class
I carcinogen by the International Agency for Research on
Cancer (IARC) and World Health Organization (WHO)
[3]. However, the pathogenesis of H. pylori infection–
induced gastric cancer has not been fully elucidated.
Angiogenesis is already present in early gastric cancer,
and its development requires a unique tumor phenotype
and necessary ingredients. As the cancer progresses
toward more advanced stages, angiogenesis becomes
more pronounced. Angiogenesis and the occurrence and
development of gastric cancer are closely related [4].
Angiogenesis is a key step in tumor growth and metasta-
sis [5]. Neovascularization not only provides nutrients
and oxygen to the tumor cells, and carries away meta-
bolic waste, but it also stimulates tumor growth through
autocrine or paracrine modes of action. It is a complex
process of angiogenesis, which is co-regulated by angio-
genic and anti-angiogenic factors. Gastric cancer cells
can produce a variety of proangiogenic growth factors
[6], and vascular endothelial growth factor (VEGF) is the
strongest and the most specific angiogenic growth fac-
tor. VEGF plays a major role in the multistep process of
angiogenesis stimulation and is closely related to the
development of gastric cancer [7]. Moreover, VEGF plays
a pivotal role in tumor-associated microvascular angio-
genesis [8] and has been demonstrated to be overex-
pressed in human gastric carcinomas [9–11]. Although
there have been numerous reports on H. pylori infection
influencing angiogenesis in gastric cancer, the exact
mechanism remains unclear.
COX is a key rate-limiting enzyme in the conversion
of arachidonic acid to prostanoids and thromboxanes; it
exists in two forms, cyclooxygenase 1 (COX-1) and
COX-2 [12, 13]. COX-1 is responsible for maintaining
normal physiological function; it is expressed constitu-
tively in most tissues. In contrast, COX-2 is an early
response gene induced by growth factors, proinflamma-
tory cytokines, tumor promoters, and bacterial toxins
[14–16]. We earlier demonstrated that H. pylori can up-
regulate COX-2 via the p38 mitogen-activated protein
kinase (MAPK)/activating transcription factor-2 (ATF-2)
signaling pathway in MKN45 gastric cancer cells [17].
Caputo et al. [18] reported that H. pylori induced VEGF
upregulation in MKN28 gastric cancer cells, which
might be mediated by COX-2. Moreover, research shows
that that H. pylori infection influences angiogenesis in
gastric cancer patients [19]. Considering these results, it
is reasonable to believe that COX-2 might play a role in
VEGF upregulation in H. pylori-infected gastric cancers.
The Wnt/beta-catenin pathway is commonly activated
during carcinogenesis [20]. In the classical Wnt signaling
pathway, Wnt binding to its Fz receptor inactivates the
beta-catenin destructive complex comprising adenoma-
tous polyposis coli (APC), axin, and glycogen synthase
kinase-3 beta (GSK3beta). Beta-catenin then disassoci-
ates from the complex, translocates into the nucleus,
and binds to members of the lymphoid-enhancing fac-
tor/T-cell factors (Tcf/Lef ) family that activate target
gene transcription when the Wnt pathway is activated
[21]. Normally, beta-catenin phosphorylation maintains
the complex in a stable state, and unphosphorylated
beta-catenin enters into the nucleus when Wnt pathway
is activated. The Wnt/beta-catenin pathway is important
for angiogenesis, and beta-catenin is associated with
COX-2 overexpression [22] and angiogenesis [23]. How-
ever, whether the Wnt/beta-catenin pathway plays a role
in H. pylori-induced angiogenesis is unclear.
In the present study, we aimed to investigate whether
the Wnt/beta-catenin pathway is involved in H. pylori-
induced upregulation of angiogenesis in gastric cancer.
Methods
H. pylori culture
The H. pylori cagA- and vacA-positive standard strain
NCTC11637 was obtained from the Institute of Di-
gestive Diseases, Renji Hospital, Shanghai Jiao Tong
University, Shanghai, China. H. pylori was cultured
on Columbia agar (Oxoid, Basingstoke Hampshire,
UK) plates containing 5 % sheep blood and incubated at
37 °C under microaerophilic conditions for 48–72 h. Col-
onies were identified as H. pylori by Gram staining, morph-
ology, and positive oxidase, catalase, and urease activities.
Bacteria were suspended in phosphate-buffered saline
(PBS) and the density was estimated by spectrophotometry
(OD600 nm) and microscopic observation.
Immunohistochemical staining of COX-2, beta-catenin,
VEGF, and CD34 in human gastric carcinoma tissues
A total of 106 different formalin-fixed, paraffin-
embedded gastric cancer tissue samples and adjacent
normal tissues were obtained from Shuguang Hospital,
Shanghai University of Traditional Chinese Medicine.
The use of all human tissue samples was approved by
the Institutional Review Board of Shuguang Hospital,
which is affiliated with Shanghai University of Trad-
itional Chinese Medicine. Informed consent was ob-
tained from every patient for the use of all human
tissues used in this study. First, tissue samples were
stained with Giemsa to determine the presence of H.
pylori infection. Next, using standard methods, COX-2,
beta-catenin, VEGF, and CD34 were detected immuno-
histochemically. Briefly, tissues were embedded in paraf-
fin and 4-μm sections were cut, deparaffinized in xylene,
Liu et al. BMC Cancer  (2016) 16:321 Page 2 of 11
and dehydrated through a graded alcohol series. Tissue
sections were subjected to peroxidase clearance, antigen
retrieval, and blocking of non-specific binding sites. Sec-
tions were first incubated with primary antibody (rabbit
polyclonal antibodies against CD34, COX-2, beta-
catenin, and VEGF (Abcam, Cambridge, MA, USA),
followed by EnVision secondary antibody (Dako,
Glostrup, Denmark). Sections were counterstained with
hematoxylin. PBS served as a negative control for pri-
mary antibody. Staining intensity was assessed in each
specimen on a scale of 0–3: 0, no staining; 1, weak stai-
ning; 2, moderate staining; and 3, strong staining.
Immunohistochemical analysis of the MVD
According to Weidner [24], areas of highest neovascu-
larization were found by scanning tumor sections at
low-power (×40) magnification. After the area of highest
neovascularization was identified, individual microvessel
counts were made in a single high-power (×200) mag-
nification field. Three different visual fields were
selected for microvessel counting, and the mean value
was recorded. Brown-staining endothelial cells or
endothelial cell clusters were considered as single,
countable microvessels.
Cell culture and reagents
SGC7901 and MKN45 gastric cancer cells were obtained
from the Institute of Digestive Diseases, Renji Hospital
of Shanghai Jiao Tong University, Shanghai, China,
and cultured in RPMI 1640(Gibco, Thermo Fisher Sci-
entific Inc, Waltham, MA, USA) containing 10 % (v/v)
fetal bovine serum (Gibco, Thermo Fisher Scientific
Inc, Waltham, MA, USA) and 1 % penicillin and
streptomycin (North China Pharmaceutical Company,
Shijiazhuang, China). Cells were plated in 6-well plates
and grown to confluency. FH535, a beta-catenin-
specific inhibitor, was obtained from Cell Signaling
(Beverly, MA, USA). All cells were grown in a humidi-
fied incubator containing 5 % CO2 at 37 °C.
Real-time fluorogenic quantitative polymerase chain
reaction
RNA isolation
Total cellular RNA was prepared using RNAisol reagent
(TaKaRa Biotechnology, Dalian, China) according to the
manufacturer’s instructions. RNAisol (1 ml) was added
to each sample and incubated for 5 min at room
temperature. Next, 200 μl chloroform was added and
samples were shaken for 15 s and incubated at room
temperature for 2-3 min and then centrifuged at
12,000 g for 15 min at 4 °C after formation of a bi-
phasic solution. For RNA precipitation, the aqueous
phase (top) was transferred to a new tube and 500 μl
isopropanol was added. Samples were incubated at
room temperature for 5-10 min and then centrifuged
at 12,000 g for 15 min at 4 °C, after which a pellet
was visible. After supernatant removal, 1000 μl of
75 % ethanol was added to wash the RNA pellet; this
was vortexed and centrifuged at 8000 g for 5 min at
4 °C. After the ethanol was carefully removed by pip-
etting, the RNA pellet was air-dried for 5-10 min and
then dissolved in diethylpyrocarbonate-treated water
with vortexing. RNA quality was verified by agarose
gel electrophoresis and visualization of 28S and 18S
ribosomal RNA. RNA was quantified by spectropho-
tometry (OD260/280 nm). RNA was then immediately
frozen at −70 °C.
cDNA synthesis and real-time quantitative analysis
Reverse transcription was conducted using a PrimeScript
RT-PCR Kit (TaKaRa Biotechnology, Dalian, China).
Total RNA (1 μg) was used as a template for cDNA syn-
thesis. Briefly, reverse transcription was carried out in a
20-μl solution including 4 μl 5× buffer, 1 μl oligo dT pri-
mer, 1 μl random 6-mers, 1 μl PrimeScript RT Enzyme
Mix, and RNAse-free deionized H2O. Reverse transcrip-
tion incubation conditions were 37 °C for 15 min and
85 °C for 5 s The resultant cDNA was stored at −20 °C
until it was used for real-time quantitative polymerase
chain reaction (PCR). Real-time PCR reactions were car-
ried out using the ABI7300 Fast Real-Time PCR System
(PE Biosystems, Foster City, CA, USA) using a Prime-
Script RT-PCR Kit according to the manufacturer’s in-
structions. Primers and probes for human GAPDH,
VEGF, and COX2 were designed and synthesized by
Shanghai Shanjing Biotechnology (Shanghai, China) with
FAM (6-carboxy-fluo-rescein-phosphoramidite)-labeled
5′ ends and TAMPA (carboxy-tetramethyl-rhodamine)-
labeled 3′ ends. Primer and probe sequences were:
human GAPDH-forward, 5′-CCACTCCTCCACCTTT
GAC-3′; human GAPDH-reverse, 5′-ACCCTGTTGC
TGTAGCCA-3′; GAPDH probe, 5′-TTGCCCTCAAC
GACCACTTTGTC-3′; human VEGF-forward, 5′-GG
CCTCCGAAACCATGAACT-3′, human VEGF-reverse,
5′-ACCCTGTTGCTGTAGCCA-3′; and VEGF probe,
5′-TGTCTT GGGTGCATTGGAGC-3′. Briefly, each
PCR was performed in a 20-μl reaction volume compris-
ing 10 μl Premix EX Taq, 0.4 μl Rox reference dye,
0.4 μl each primer, 0.8 μl TaqMan probe, 6 μl deionized
H2O and 2 μl cDNA. PCR cycling conditions were 95 °C
for 10 s, followed by 40 cycles of 95 °C for 5 s (denatur-
ation) and 60 °C for 31 s (annealing/extension). Each
reaction was performed in triplicate, and data were ana-
lyzed by the 2−ΔΔCt method for comparing relative ex-
pression levels. GAPDH mRNA was used to normalize
RNA levels from the various samples and mRNA expres-
sion was expressed as relative to the basal level without
H. pylori stimulation.
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Western blot analysis
Following treatment, cells were washed twice with ice-
cold PBS and then protease inhibitors (Roch, Basel,
Switzerland) were added. Cells were then scraped off the
dish, and then cytoplasmic and nuclear fractions were
prepared using a protein extraction kit (Fermentas,
Waltham, MA, USA). Cell lysis buffer, nuclei washing
buffer, and other reagent buffers were added to separate
cytosolic proteins and nuclear proteins. The protein con-
centration in extracts was determined by bicinchoninic
acid protein assay using a commercial kit (BCA Protein
Assay Reagent; Merck, Whitehouse Station, NJ, USA).
Protein samples were separated by 10 % SDS-PAGE and
transferred to PVDF membrane. The membrane was in-
cubated in blocking buffer (10 mmol/l Tris, pH 7.5,
100 mmol/l NaCl, 0.1 % Tween 20), containing 5 % non-
fat powdered milk for 1 h. The membrane was then
incubated with anti-phospho-beta-catenin or anti- beta-
catenin polyclonal antibody (1:500; Cell Signaling Tech-
nology, USA). Following overnight incubation at 4 °C,
blots were washed three times in TBS-Tween (0.05 %)
solution and incubated with goat anti-rabbit antibodies
conjugated to horseradish peroxidase (HRP) for 1 h at
room temperature before visualizing using the Pierce ECL
kit (Thermo Fisher Scientific Inc, Waltham, MA, USA).
Results were analyzed by Image J software (NIH Image).
Enzyme-linked immunosorbent assay
Cell culture supernatant samples were collected and
clarified at 3000 g for 5 min. ELISA was performed
according to the manufacturer’s protocol. Briefly, micro-
titer plates were incubated with 100 μl samples at 37 °C
for 120 min. After five washes in 10 mM PBS, plates
were incubated with 100 μl anti-VEGF primary antibody
labeled with biotin (from the ELISA kit) at 37 °C for
60 min. After five rinses with 10 mM PBS, 100 μl avidin-
biotin-peroxidase complex was added to wells and incu-
bated at 37 °C for 30 min. After extensive rinsing,
100 μl/well TMB Microwell Substrate and was added
and plates were incubated in the dark at 37 °C for
15 min. The reaction was then stopped with 100 μl
TMB stop solution and OD450 nm values were obtained
within 30 min using a microplate reader. Finally, protein
concentrations were determined from OD values using a
calibration curve.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS version 19.0). Statis-
tical significance was determined by t tests and one-way
ANOVA followed by Fisher’s least significant difference
test and differences in rates were determined by the chi-
squared test. Data are presented as means ± SE and a P
value of <0.05 was considered statistically significant.
Results
H. Pylori infection correlates with COX-2, VEGF, and
beta-catenin upregulation and angiogenesis in gastric
cancer
To investigate a correlation between H. pylori and gas-
tric cancer, we first observed H. pylori colonization in
106 gastric cancer tissues. The results showed that H.
pylori colonization is present in 36.8 % (39/106) of gas-
tric carcinoma samples. Immunohistochemical analysis
of gastric carcinomas and matched normal mucosa
showed that the mean staining intensity of COX-2 in H.
pylori-positive gastric carcinoma was 2.26 ± 0.17, signifi-
cantly higher than in H. pylori-negative gastric cancer
tissues (0.63 ± 0.16, P < 0.01; Fig. 1a, b). Similarly, the
mean VEGF staining intensity in H. pylori-positive gas-
tric carcinoma was significantly higher than in H. pylori-
negative tissues (2.65 ± 0.11 vs 0.85 ± 0.06, P < 0.01;
Fig. 1c, d). H. pylori-positive gastric cancers had a sig-
nificantly higher staining intensity for beta-catenin in
the gastric mucosa compared with H. pylori-negative
gastric cancers (1.95 ± 0.09 vs 0.45 ± 0.075, P < 0.01;
Fig. 1e, f ). Blood vessel counts in H. pylori-positive and
H. pylori-negative gastric cancer tissues showed that the
microvessel density (MVD) was 42.9 ± 4.9 and 18.1 ± 3.5,
respectively (P < 0.01; Fig. 1g, h). The presence of H. pyl-
ori infection in gastric cancer was not related to sex or
age, but correlated with the depth of tumor invasion,
lymph node metastasis, and tumor–node–metastasis
stage(P < 0.05 Table 1) and correlated with the COX-2
expression and beta-catenin expression(P < 0.01 Table 1).
These results suggest that H. pylori infection promotes
COX-2, VEGF, and beta-catenin upregulation and
increases MVD in gastric cancer, which might play an
important role in gastric cancer development.
Effect of H. pylori on VEGF mRNA and protein levels in
SGC7901 and MKN45 cells
To further confirm the VEGF upregulation in H. pylori-
infected gastric carcinomas, we investigated the effect of
H. pylori infection in gastric cancer cells on VEGF ex-
pression in vitro. After 6, 12, and 24 h incubation with
H. pylori NCTC11637 strain, there was differential up-
regulation of VEGF mRNA in SGC7901 and MKN45
cells (Fig. 2a). To assess whether H. pylori upregulation
of VEGF also occurred at the protein level, we measured
VEGF at 6, 12, 24, 36, and 48 h in H. pylori-treated or
untreated (control) MKN45 cells by ELISA (Fig. 2b).
These data further suggest that the VEGF is upregulated
by H. pylori infecting SGC7901 and MKN45 cells.
H. pylori upregulates VEGF via COX-2
We previously reported that H. pylori upregulates
COX-2 expression in vitro. To further verify whether
VEGF expression is influenced by incubation with the
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selective COX-2 inhibitor NS398, real-time fluoro-
genic quantitative (RFQ) PCR analysis and western
blotting were performed to measure VEGF mRNA
and protein levels in SGC7901 and MKN45 cells. As
shown in Fig. 3a and b, NS398 treatment of did not
obviously affect basal VEGF mRNA or protein levels
compared with the control group. Interestingly, higher
VEGF levels were observed in SGC7901 and MKN45
cells infected with H. pylori; however, this was down-
regulated by COX-2 inhibition.
In our previous studies, the lenti-virus based RNAi of
COX-2(pFU-GW-COX-2-shRNA) was constructed to
suppress the endogenous COX-2 specially [25]. To fur-
ther examine the effect of COX-2 on VEGF expression,
we infected human gastric cancer SGC7901 and MKN45
cells with the lpFU-GW-COX-2-shRNA to suppress
COX-2 expression. RFQ-PCR and western blotting
showed that COX-2 gene silencing significantly de-
creased COX-2 mRNA and protein levels in SGC7901
and MKN45 cells. COX-2 gene silencing or COX-2
pathway inhibition also reduced VEGF levels (Fig. 3c).
Considered together, our findings suggest that H. pylori
upregulates VEGF in SGC7901 and MKN45 cells via
increasing COX-2 expression.
Activation of the Wnt/beta-catenin pathway by H. pylori
infection
To identify whether the Wnt/beta-catenin pathway is
involved in VEGF upregulation after H. pylori infec-
tion, we initially observed the effects of H. pylori
infection on beta-catenin levels in SGC7901 and
MKN45 cells. Western blot analysis with phospho-
specific antibodies showed a time-dependent decrease
in beta-catenin phosphorylation in the cytoplasm.
Fig. 1 Immunohistochemical assessment of COX-2, beta-catenin,
and VEGF expression, and MVD in human gastric cancers. a COX-2
expression in H. pylori-negative gastric cancer tissues. b. COX-2
expression in H. pylori-positive gastric cancer tissues. c VEGF
expression in H. pylori-negative gastric cancer tissues. d VEGF
expression in H. pylori-positive gastric cancer tissues. e Beta-catenin
expression in H. pylori-negative gastric cancer tissues. f. Beta-catenin
expression in H. pylori-positive gastric cancer tissues. g MVD in H.
pylori-negative gastric cancer tissues. h MVD in H. pylori-positive
gastric cancer tissues. Red arrows indicate positive staining.
Magnification, ×200. NOTE: Specimens were obtained from 106
patients who underwent major surgical resection for gastric
cancer with no preoperative chemotherapy and radiotherapy
between February 2009 and December 2014 at the Department
of Surgery, Shuguang Hospital (affiliated with Shanghai University
of Traditional Chinese Medicine, Shanghai, PR China)
Table 1 Relationship between H. pylori infection, COX-2 and
beta-catenin expression, and clinicopathological features in
gastric cancer
Parameters N H. pylori-positive H. pylori-negative P value
Age/year
< 65 66 25 41 >0.05
> 65 40 14 26
Sex
Male 68 27 41 >0.05
Female 38 12 26
T classification
T1–2 36 8 28 <0.05
T3–4 70 31 39
Lymph node metastasis
Yes 76 33 43 <0.05
No 30 6 24
TNM stage
I II 37 8 29 <0.05
III IV 69 31 38
COX-2 expression
Low 35 5 30 <0.01
High 71 34 37
Beta-catenin expression
Low 41 7 34 <0.01
High 65 32 33
Liu et al. BMC Cancer  (2016) 16:321 Page 5 of 11
However, H. pylori induced cytoplasmic and nuclear
beta-catenin accumulation, showing that H. pylori
infection could cause nuclear translocation of beta-
catenin (Fig. 4). This phenomenon demonstrated that
Wnt/beta-catenin might contribute to the H. pylori-
induced VEGF transcription.
Blocking Wnt/beta-catenin attenuates H. pylori-induced
VEGF upregulation in SGC7901 and MKN45 cells
Because H. pylori clearly induced the translocation of
beta-catenin, additional studies were carried out with
inhibitors of beta-catenin to determine the significance of
Wnt/beta-catenin signaling pathways in H. pylori-induced
Fig. 2 Time-dependent VEGF induction by H. pylori in SGC7901 and MKN45 cells. a VEGF mRNA expression increased in H. pylori-treated cells.
Confluent SGC7901 and MKN45 cells were incubated with 100 H. pylori bacteria/cell for 0, 6, 12, 24, and 36 h and then analyzed by real-time quantitative
PCR to determine VEGF mRNA expression relative to GAPDH mRNA. **P< 0.01, 12 h versus 0 h in SGC7901 and MKN45 cells. b VEGF protein content
was increased in H. pylori-treated cells. SGC7901 and MKN45 cells were incubated with H. pylori for 0, 6, 12, 24, 36, and 48 h, and then analyzed by ELISA
to determine VEGF protein levels. **P < 0.01, 24 h versus 0 h in SGC7901 cells; △△P < 0.01, 36 h versus 0 h in MKN45 cells
Fig. 3 COX-2 inhibition attenuates H. pylori-induced VEGF upregulation in SGC7901 and MKN45 cells. a The COX-2 inhibitor NS398 attenuated H.
pylori-dependent VEGF mRNA induction. Confluent SGC7901 and MKN45 cells were pretreated with 50 μM NS398 for 2 h prior to culture with or
without H. pylori for 12 h. VEGF mRNA expression relative to GAPDH mRNA was determined by quantitative RT-PCR. **P < 0.01 for H. pylori-infected
vs control cells. b NS398 attenuated H. pylori induction of VEGF protein. SGC7901 and MKN45 cells were pretreated with 50 μM NS-398 for 2 h
prior to culture with or without H. pylori for 24 h and 36 h. The culture supernatant was then analyzed by ELISA to determine VEGF protein
content. **P < 0.01 for H. pylori-infected vs control SGC7901 and MKN45 cells. c RNAi-mediated COX2 inhibition blocked VEGF upregulation by
H. pylori. Confluent SGC7901 and MKN45 cells were infected with pFU-GW-COX-2-shRNA for 72 h with or without H. pylori treatment for 48 h.
VEGF protein content in culture supernatant was then measured by ELISA. **P < 0.01 for H. pylori-infected vs control cells
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VEGF upregulation. We found that H. pylori-induced
VEGF mRNA and protein upregulation was partially
blocked by FH535 (a specific inhibitor of beta-catenin ac-
tivity, 20 μM; Fig. 5). Thus, the Wnt/beta-catenin signaling
pathway might be primarily responsible for H. pylori-in-
duced VEGF upregulation in SGC7901 and MKN45 cells.
COX-2 inhibition attenuates H. pylori-induced effects on
beta-catenin expression in SGC7901 and MKN45 cells
To determine whether COX-2 is responsible for Wnt/
beta-catenin activation, SGC7901 and MKN45 cells were
transfected with pFU-GW-COX-2-shRNA or the COX-2
inhibitor NS398 (50 μM, 2 h). After COX-2 gene silen-
cing or COX-2 pathway inhibition, cytoplasmic and
nuclear beta-catenin protein levels were significantly
inhibited, showing that COX-2 is partly responsible for
Wnt/beta-catenin activation (Fig. 6).
Discussion
Malignant tumor growth and metastasis are complex
processes related not only to the characteristics of the
tumor itself but also to those of the tumor growth
environment. Numerous studies have shown that in-
creased MVD is an important feature of the tumor
growth environment, which is a key factor in promot-
ing tumor growth. H. pylori-induced angiogenesis in
the gastric mucosa is important for the occurrence
and development of gastric cancer. We first observed
H. pylori colonization, COX-2, VEGF, beta-catenin
levels and MVD in gastric cancer tissues. We found
that approximately one third of gastric cancer tissues
have H. pylori colonization, which is not a very high
proportion. This suggests that many factors lead to
gastric cancer development and H. pylori is only one
of these. This may also explain why the gastric
Fig. 4 H. pylori affects phospho-beta-catenin and unphosphorylated beta-catenin protein levels in SGC7901 and MKN45 cells. Confluent SGC7901
and MKN45 gastric cancer cells were incubated with H. pylori at 100 bacteria/cell for 2, 6, 12, 24, and 48 h, and then p-beta-catenin and
unphosphorylated beta-catenin protein levels were determined in total cellular protein extracts by western blotting. Blots were stripped
and reprobed with beta-actin or PCNA to show equal protein loading. The experiment was performed for three times with similar results.
a H. pylori attenuates cytoplasmic p-beta-catenin protein levels in SGC7901 and MKN45 cells. **P < 0.01 for 6 h versus 0 h in SGC7901
cells; △△P < 0.01 for 12 h versus 0 h in MKN45 cells. b H. pylori induces cytoplasmic beta-catenin accumulation in MKN45 cells. **P < 0.01
for 12 h versus 0 h in SGC7901 and MKN45 cells. c H. pylori induces nuclear beta-catenin accumulation in SGC7901 and MKN45 cells.
**P < 0.01 for 12 h versus 0 h in SGC7901 and MKN45 cells
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mucosa can no longer support H. pylori survival after
gastric carcinogenesis. We also found that COX-2,
VEGF, and beta-catenin expression and MVD were
significantly higher in H. pylori-positive gastric cancer
tissues than in H. pylori-negative gastric cancer tis-
sues, indicating that H. pylori plays an important role
in blood vessel formation in gastric cancer.
Some investigators have suggested an association
between H. pylori infection and angiogenesis. Sasaki
et al. previously reported tumor vascularity was
greater in H. pylori-infected gastric cancer patients
than in gastric cancer patients after H. pylori eradica-
tion [26]. H. pylori heat shock protein 60 (HSP60) en-
hances angiogenesis via CXCR2/PLCbeta2/Ca2+ signal
transduction in HUVECs [27], but until now, the
mechanism of H. pylori induced angiogenesis has
remained poorly understood.
Tumor angiogenesis results from an imbalance be-
tween positive and negative angiogenic factors re-
leased by tumor and host cells into the neoplastic
tissue microenvironment [28]. Gastric cancer cells
produce many angiogenic factors, including VEGF,
interleukin-8 and platelet-derived endothelial growth
factor. Furthermore, H. pylori infection increases the
expression of these angiogenic factors. Of these,
VEGF is the key regulator of tumor-associated angio-
genesis. The mechanism of H. pylori-induced VEGF
upregulation is complicated and unclear. Our previous
study found that the p38 MAPK-COX-2-EP2/EP4 axis
regulates H. pylori-induced VEGF upregulation in
gastric cells, providing a theoretical basis for investi-
gating the pathogenesis of H. pylori-induced gastric
cancer [25]. H. pylori also stimulates host VEGF gene
expression via MEK/ERK-dependent activation of Sp1
and Sp3 [29]. Our findings suggest that infection with
H. pylori standard strain NCTC11637 leads to a re-
markable increase in VEGF expression in SGC7901
and MKN45 gastric epithelial cells via increasing the
expression of COX-2, an important factor in gastric
cancer development.
Many studies have shown that multiple intracel-
lular pathways are activated by H. pylori [30–33],
including the Wnt/beta-catenin pathway [34]. In the
absence of Wnt signaling, beta-catenin is present in
the cellular beta-catenin destruction complex. This
multiprotein complex contains axin and adenomatous
APC scaffolds that bind beta-catenin to facilitate its
phosphorylation by casein kinase 1 (CKI) at Ser-45
and by GSK3beta at Ser-33, Ser-37, and Thr-41 [35];
it is targeted for degradation by the proteasome.
Wnt pathway activation leads to depolymerization of
the destruction complex, resulting in cytoplasmic
beta-catenin accumulation and further transcription
in the nucleus [36, 37]. The Wnt/beta-catenin path-
way is involved in the development of a variety of
malignant tumors, including gastric cancer [35, 38].
The H pylori cag secretion system activates beta-
catenin, p120, and PPARδ, which promote gastric
epithelial cell proliferation and might therefore con-
tribute to gastric adenocarcinoma development in
humans [39]. Studies have also shown that the Wnt/
beta-catenin signaling plays an important role in gas-
tric cancer angiogenesis. Beta-catenin is an important
part of the angiogenesis pathway [40, 41]. However,
the role of Wnt/beta-catenin in gastric cancer angio-
genesis and the mechanism responsible for this re-
main to be elucidated.
Our results have demonstrated that H. pylori
infection upregulates COX-2, which reduces cyto-
plasmic beta-catenin protein phosphorylation and
induces cytoplasmic and nuclear beta-catenin accu-
mulation, thus showing that H. pylori infection can
induce the nuclear translocation of beta-catenin. We
also confirmed that H pylori stimulates gastric epi-
thelial cells to secrete VEGF, a proangiogenic factor,
via the COX-2/Wnt/beta-catenin pathway, which
may be an important drug target for preventing and
treating H. pylori infection. Future studies should
aim to determine which bacterial components induce
angiogenesis in H. pylori-infected cells. Moreover,
COX-2 and Wnt inhibitors have been used to treat
tumors in clinical trials, and further studies may re-
veal whether these inhibitors can be used to treat
gastric cancer [42].
Fig. 5 Beta-catenin inhibition attenuates H. pylori-induced VEGF
upregulation in SGC7901 and MKN45 cells. Confluent SGC7901 and
MKN45 cells were pretreated with 20 μM FH535 for 2 h prior to
culture with or without H. pylori for 12 h. Relative cellular VEGF
protein levels were then measured by ELISA. **P < 0.01 for H.
pylori-infected versus control cells
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Conclusions
This study indicates H. pylori infection correlated with
the depth of tumor invasion, degree of lymph node
metastasis, and TNM stage. Moreover, H. pylori infec-
tion promoted COX-2, VEGF, and beta-catenin expres-
sion and increased MVD in gastric cancer. Further
studies revealed that H. pylori infection induces VEGF
upregulation via the COX-2/Wnt/beta-catenin pathway.
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